Point72 Asset Management L.P. cut its holdings in Nevro Corp (NYSE:NVRO) by 37.1% during the second quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 148,376 shares of the medical equipment provider’s stock after selling 87,583 shares during the period. Point72 Asset Management L.P. owned 0.48% of Nevro worth $9,619,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Nevro by 4.0% in the 2nd quarter. Vanguard Group Inc. now owns 2,670,677 shares of the medical equipment provider’s stock worth $173,140,000 after purchasing an additional 102,183 shares in the last quarter. BlackRock Inc. lifted its holdings in Nevro by 1.2% in the 2nd quarter. BlackRock Inc. now owns 2,583,530 shares of the medical equipment provider’s stock worth $167,491,000 after purchasing an additional 29,637 shares in the last quarter. Invesco Ltd. lifted its holdings in Nevro by 316.2% in the 2nd quarter. Invesco Ltd. now owns 1,970,969 shares of the medical equipment provider’s stock worth $127,778,000 after purchasing an additional 1,497,455 shares in the last quarter. Northern Trust Corp lifted its holdings in Nevro by 5.3% in the 2nd quarter. Northern Trust Corp now owns 381,354 shares of the medical equipment provider’s stock worth $24,724,000 after purchasing an additional 19,214 shares in the last quarter. Finally, Rock Springs Capital Management LP lifted its holdings in Nevro by 463.4% in the 2nd quarter. Rock Springs Capital Management LP now owns 195,500 shares of the medical equipment provider’s stock worth $12,674,000 after purchasing an additional 160,800 shares in the last quarter.

A number of research analysts recently commented on the company. Northland Securities set a $65.00 price target on Nevro and gave the stock a “hold” rating in a report on Friday, August 9th. Leerink Swann set a $98.00 price target on Nevro and gave the stock a “buy” rating in a report on Friday, August 23rd. Zacks Investment Research raised Nevro from a “sell” rating to a “hold” rating and set a $67.00 price objective on the stock in a research note on Tuesday, August 13th. Canaccord Genuity lifted their price objective on Nevro from $50.00 to $59.00 and gave the stock a “hold” rating in a research note on Friday, August 9th. Finally, JMP Securities lifted their price objective on Nevro from $70.00 to $90.00 and gave the stock a “market outperform” rating in a research note on Monday, August 12th. Two analysts have rated the stock with a sell rating, four have given a hold rating, six have issued a buy rating and one has assigned a strong buy rating to the company. The company presently has an average rating of “Hold” and a consensus price target of $65.83.

NYSE:NVRO traded down $0.75 during trading hours on Monday, reaching $89.16. The stock had a trading volume of 3,443 shares, compared to its average volume of 314,101. The company has a debt-to-equity ratio of 0.89, a quick ratio of 4.66 and a current ratio of 6.05. Nevro Corp has a 52 week low of $34.75 and a 52 week high of $91.60. The company has a 50 day moving average price of $80.71 and a two-hundred day moving average price of $65.65. The stock has a market capitalization of $2.76 billion, a PE ratio of -54.43 and a beta of 0.21.

Nevro (NYSE:NVRO) last released its quarterly earnings data on Thursday, August 8th. The medical equipment provider reported ($0.91) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.89) by ($0.02). Nevro had a negative return on equity of 41.07% and a negative net margin of 24.51%. The firm had revenue of $93.60 million during the quarter, compared to the consensus estimate of $88.40 million. During the same period in the previous year, the firm earned ($0.35) EPS. The business’s revenue was down 2.6% compared to the same quarter last year. Equities research analysts predict that Nevro Corp will post -3.87 EPS for the current year.

Nevro Profile

Nevro Corp., a medical device company, provides products for the patients suffering from chronic pain in the United States and internationally. The company develops and commercializes the Senza spinal cord stimulation system, an evidence-based neuromodulation platform for the treatment of chronic pain.

Featured Story: Reverse Stock Split

Want to see what other hedge funds are holding NVRO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Nevro Corp (NYSE:NVRO).

Institutional Ownership by Quarter for Nevro (NYSE:NVRO)

Receive News & Ratings for Nevro Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Nevro and related companies with MarketBeat.com's FREE daily email newsletter.